Clear cell renal cell carcinoma+2
Not yet recruitingPhase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma
Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma
- Disease:Clear cell renal cell carcinomaRenal cell carcinoma+1
- Substances:CabozantinibIpilimumab
Italy- Participants:18–64 years · 65+ years
- Substances:Cabozantinib
- Sponsor:Bristol-Myers Squibb Services Unlimited Company









